The American Academy of Dermatology (AADA) and the New York State Society of Dermatology and Dermatologic Surgery have issued an official statement supporting a New York City Council investigation into medspas, placing two of the most influential dermatology bodies in the United States squarely behind municipal-level scrutiny of the medical aesthetics sector.

The joint statement, published by The Dermatology Digest, positions organized dermatology as an ally — not an opponent — of regulators examining how medspas operate in one of the country's largest aesthetics markets. For professionals who treat clients in or alongside medspa settings, the endorsement matters because it signals where clinical dermatology's professional bodies stand on supervision, safety standards and scope-of-practice questions that have circled the sector for years.

New York City's move to investigate medspas reflects a broader pattern: state and municipal authorities across the U.S. have intensified attention on facilities that offer procedurally invasive treatments — energy-based devices, injectables and laser procedures among them — in environments that do not always involve physician-led care. The AADA's decision to attach its name to the New York City Council effort gives the investigation institutional clinical backing from a national organization representing thousands of dermatologists.

For practice owners and compliance teams, the development carries a clear message: jurisdictions with major aesthetics markets are increasingly willing to examine who performs which procedures, under what supervision, and with what documentation. A City Council investigation supported by the AADA and the New York State Society of Dermatology and Dermatologic Surgery could produce findings that shape future licensing, oversight or disclosure requirements for medspas operating in the five boroughs — and potentially inform parallel efforts elsewhere in New York State.

The involvement of the New York State Society of Dermatology and Dermatologic Surgery adds a state-level clinical voice to a city-level process. That pairing suggests the societies view the investigation as a step toward clearer accountability in a market where medical treatments are frequently delivered in retail-adjacent settings, often marketed as wellness services rather than medical care.

For dermatologists and dermatologic surgeons practicing in New York, the statement offers a degree of professional validation: their societies are actively engaging with regulators on the conditions under which aesthetic medical treatments reach consumers. For medspa operators, procurement and treatment-menu planning may need to account for a stricter supervisory environment if the investigation's findings translate into legislative or regulatory action.

The official statement also serves a consumer-safety framing. By supporting the Council's investigation, the AADA and the state society are effectively endorsing public examination of adverse-event risks, staffing models and treatment protocols in medspas — themes that dermatology organizations have raised in other jurisdictions through scope-of-practice advocacy and safety campaigns.

What comes next is the investigation itself. Stakeholders should watch for the New York City Council's hearing schedule, any witness lists that include dermatology societies or medspa industry representatives, and ultimately any report or legislative proposal that emerges. Regulatory filings following the investigation would mark the first concrete test of whether municipal scrutiny in New York becomes a template for oversight of the medspa sector nationwide.